Madhavan: (con't) ID'd a ROS1 fusion, enrolled into trial, 7mos in still 'doing well' IGNYTA trial #BHCRForum18 https://t.co/obhw5WeLa5

11:47am April 23rd 2018 via Twitter Web Client